Compare Natera Inc. Common Stock (NTRA) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Invesco S&P 500 High Div Low Volatility ETF trades at $49.78 (market cap $3.20B). The key difference: Natera Inc. Common Stock is far larger — about 17.8× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Invesco S&P 500 High Div Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Invesco S&P 500 High Div Low Volatility ETF for 126 Days on average.
| NTRA | SPHD | |
|---|---|---|
Market Cap | $57.03B | $3.20B |
Volume | 1,131,157 | 1,075,230 |
Sector | Health | — |
52-Week High | $425.64 | $53.55 |
52-Week Low | $179.42 | $46.96 |
Typical Hold Time | 0 Days | 126 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SPHD, the Invesco S&P 500 High Dividend Low Volatility ETF, trades at $49.29, up 0.1% on the day. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages, while the RSI suggests mild overbought conditions. The ETF focuses on high dividend yields and low volatility, attracting income-focused investors, though recent news highlights performance comparisons with peers like SCHD.
The outlook for SPHD hinges on its dividend strategy amid market volatility. Opportunities include steady income for retirees, but risks involve underperformance versus growth-focused ETFs and sensitivity to interest rate changes. Investors should weigh the trade-off between yield and total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
